.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,068,859

« Back to Dashboard
Patent 6,068,859 protects ZMAX and is included in one NDA. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has forty-eight patent family members in thirty-eight countries.

Summary for Patent: 6,068,859

Title: Controlled-release dosage forms of Azithromycin
Abstract:A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.
Inventor(s): Curatolo; William J. (Niantic, CT), Friedman; Hylar L. (Brattleboro, VT), Korsmeyer; Richard W. (Old Lyme, CT), LeMott; Steven R. (East Lyme, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:08/727,634
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Device; Use; Process; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 21st percentile
Forward Citations: 7th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pf Prism Cv
ZMAX
azithromycin
FOR SUSPENSION, EXTENDED RELEASE;ORAL050797-001Jun 10, 2005RXYes6,068,859► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,068,859

PCT Information
PCT FiledApril 13, 1995PCT Application Number:PCT/IB94/00264
PCT Publication Date:November 16, 1995PCT Publication Number: WO95/30422

Non-Orange Book Patents for Patent: 6,068,859

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,108,865Controlled-release dosage forms of azithromycin► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,068,859

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)548► subscribe
African Regional IP Organization (ARIPO)9500735► subscribe
Austria209497► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc